+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Influenza A virus H5N1 subtype Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A virus H5N1 subtype

  • ID: 4629654
  • Report
  • September 2018
  • Region: Global
  • 65 pages
  • VPA Research

FEATURED COMPANIES

  • Abzyme Therapeutics LLC
  • Aphios Corp
  • Cocrystal Pharma Inc
  • Greffex Inc
  • Medigen Inc
  • Shionogi & Co Ltd
  • MORE
Influenza A virus H5N1 subtype Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Influenza A virus H5N1 subtype Infection pipeline products.

Report Description

The Influenza A virus H5N1 subtype Infection pipeline guide presents complete overview of drugs currently being developed for Influenza A virus H5N1 subtype Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Influenza A virus H5N1 subtype Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Influenza A virus H5N1 subtype Infection pipeline candidates is included.

Major companies participating in therapeutic development of Influenza A virus H5N1 subtype Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Influenza A virus H5N1 subtype Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Influenza A virus H5N1 subtype Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Influenza A virus H5N1 subtype Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Influenza A virus H5N1 subtype Infection pipeline report includes
  • Panorama of Influenza A virus H5N1 subtype Infection pipeline markets including statistics on therapeutic drugs and companies involved
  • Influenza A virus H5N1 subtype Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered
  • Influenza A virus H5N1 subtype Infection pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Influenza A virus H5N1 subtype Infection pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Influenza A virus H5N1 subtype Infection pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Influenza A virus H5N1 subtype Infection pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Influenza A virus H5N1 subtype Infection pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abzyme Therapeutics LLC
  • Aphios Corp
  • Cocrystal Pharma Inc
  • Greffex Inc
  • Medigen Inc
  • Shionogi & Co Ltd
  • MORE
I. Key Findings

1. Companies Investing in Influenza A virus H5N1 subtype Infection Pipeline include-
Number of Companies with Influenza A virus H5N1 subtype Infection projects in pre-clinical Development-
Number of Companies with Influenza A virus H5N1 subtype Infection projects in Clinical Development-
Influenza A virus H5N1 subtype Infection Pipeline Companies based in Americas
Influenza A virus H5N1 subtype Infection Pipeline Companies based in Europe
Influenza A virus H5N1 subtype Infection Pipeline Companies based in Asia Pacific
Influenza A virus H5N1 subtype Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include-
Influenza A virus H5N1 subtype Infection Pipeline Agents in pre- clinical/ Discovery stage of Development
Influenza A virus H5N1 subtype Infection Pipeline Agents in Clinical Development stage
Influenza A virus H5N1 subtype Infection Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs-
Small molecules among the Influenza A virus H5N1 subtype Infection Pipeline agents

II. Insights into Influenza A virus H5N1 subtype Infection Pipeline -

1. Disease Overview
Introduction to Influenza A virus H5N1 subtype Infection
Symptoms and Causes of Influenza A virus H5N1 subtype Infection
Treatment or Prevention Options for Influenza A virus H5N1 subtype Infection
Other Details
2. Phase wise Pipeline Compounds
Influenza A virus H5N1 subtype Infection Pipeline- Pre- Clinical/ Discovery stage Drugs
Influenza A virus H5N1 subtype Infection Pipeline- Phase 1 stage Drugs
Influenza A virus H5N1 subtype Infection Pipeline- Phase 2 stage Drugs
Influenza A virus H5N1 subtype Infection Pipeline- Phase 3 stage Drugs
Influenza A virus H5N1 subtype Infection Pipeline- Pre-Registration stage Drugs
3. Company wise Influenza A virus H5N1 subtype Infection Pipeline Compounds
4. Influenza A virus H5N1 subtype Infection Pipeline by Mechanism of Action

III. Influenza A virus H5N1 subtype Infection Pipeline Compound Details
  • Neuraminidase inhibitor for H5N1
  • avian influenza vaccine
  • Pandemic influenza H5 and H1B vaccine
  • NasoVAX
  • Influenza A virus H5N1 vaccine
  • APP-0205
  • APP-309
  • MD 2009
  • BVX-M001
  • Nasal influenza vaccines
  • peptide treatment for H5N1
  • Small Molecules for Influenza A Virus H5N1
  • CHO-S05
  • CC-42344
  • CV7302
  • DP-C005
  • PN-SIA 49
  • PN-SIA 28
  • sirtuin-targeted drugs for influenza virus
  • GammaFlu
  • siRNA antivirals
  • GREFLU/VIE
  • Ampligen
  • KPT-335
  • KIN 1148
  • Influ-nRNA
  • H5N1 virus-like particle vaccine
  • influenza (H5, H7, H9 and H10 )VLP vaccine
  • AT-301
  • FLU-CIDE
  • GelVac vaccine
  • influenza H5N1 vaccine
  • influenza virus haemagglutinin glycoprotein inhibitors
  • Baloxavir Marboxil
  • MV-4
  • Pandemic H5N1 vaccine
  • split-virion H5N1 vaccine
  • VX-787
  • HB36.6
Drug Details

1. Snapshot-
Name of the Therapeutic Agent
Originator
Developing Company
Co-Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Influenza A virus H5N1 subtype Infection Pipeline Company Briefs
  • Abzyme Therapeutics LLC
  • Akshaya Bio Inc
  • AlphaVax
  • Altimmune Inc
  • Antigen Express Inc
  • Aphios Corp
  • Aphios Corp
  • AusBio Ltd
  • BiondVax Pharmaceuticals Ltd
  • CaPtivate Pharmaceuticals LLC
  • CEL-SCI Corp
  • Chicago Biosolutions Inc
  • CHO Pharma Inc
  • Cocrystal Pharma Inc
  • Curevac AG
  • Declion Pharmaceuticals Inc
  • Fides Pharma SPA
  • Fides Pharma SPA
  • Forge Life Science LLC
  • Gamma Vaccines Pty Ltd
  • General Research Laboratory
  • Greffex Inc
  • Hemispherx Biopharma Inc
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • Lakewood-Amedex Inc
  • Medicago Inc
  • Medigen Inc
  • Medigen Vaccine Biologics Corp
  • NanoViricides Inc
  • Ology Bioservices Inc
  • OPKO Health Inc
  • PeptiDream Inc
  • Shionogi & Co Ltd
  • TGV Laboratories Inc
  • Tria Bioscience Corp
  • Vaxine Pty Ltd
  • Vertex Pharmaceuticals
  • Virvio Inc
V. Latest News and Developments in Global Influenza A virus H5N1 subtype Infection Pipeline Market

VI. Appendix
1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability"
Note: Product cover images may vary from those shown
  • Abzyme Therapeutics LLC
  • Akshaya Bio Inc
  • AlphaVax
  • Altimmune Inc
  • Antigen Express Inc
  • Aphios Corp
  • AusBio Ltd
  • BiondVax Pharmaceuticals Ltd
  • CaPtivate Pharmaceuticals LLC
  • CEL-SCI Corp
  • Chicago Biosolutions Inc
  • CHO Pharma Inc
  • Cocrystal Pharma Inc
  • Curevac AG
  • Declion Pharmaceuticals Inc
  • Fides Pharma SPA
  • Forge Life Science LLC
  • Gamma Vaccines Pty Ltd
  • General Research Laboratory
  • Greffex Inc
  • Hemispherx Biopharma Inc
  • Karyopharm Therapeutics Inc
  • Kineta Inc
  • Lakewood-Amedex Inc
  • Medicago Inc
  • Medigen Inc
  • Medigen Vaccine Biologics Corp
  • NanoViricides Inc
  • Ology Bioservices Inc
  • OPKO Health Inc
  • PeptiDream Inc
  • Shionogi & Co Ltd
  • TGV Laboratories Inc
  • Tria Bioscience Corp
  • Vaxine Pty Ltd
  • Vertex Pharmaceuticals
  • Virvio Inc
Note: Product cover images may vary from those shown
Adroll
adroll